Finally, although still experimental, gene therapy targeting eNOS expression or TGF-β inhibition has shown promising antifibrotic effects in preclinical models, offering a future avenue for personalized medicine in CRS [98,104]. The gene discussed is NOS3; the disease is congenital rubella syndrome.